Drug Profile
Alnuctamab - EngMab
Alternative Names: ALNUC; BMS-986349; CC-93269; EM-901Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator EngMab
- Developer Celgene Corporation; EngMab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- Preclinical Diffuse large B cell lymphoma
- No development reported Haematological malignancies
Most Recent Events
- 27 Feb 2024 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Israel and USA (unspecified route) (NCT061638980 (700369505)
- 31 Jan 2024 Celgene plans a phase III ALUMMINATE RRMM trial for Multiple myeloma in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, South Korea, the Netherlands, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom and USA (NCT06232707)
- 11 Dec 2023 Bristol Myers Squibb plans a phase III trial for Multiple myelona(second-line therapy or greater) (SC) in the first half of 2024